bicalutamide and Obesity

bicalutamide has been researched along with Obesity in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (33.33)	29.6817
2010's	1 (33.33)	24.3611
2020's	1 (33.33)	2.80

Authors

Authors	Studies
Bilusic, M; Dahut, WL; Donahue, RN; Geynisman, DM; Ghatalia, P; Gulley, JL; Karzai, F; Madan, RA; Plimack, ER; Ross, EA; Schlom, J; Toney, NJ; Wroblewski, S; Zibelman, M	1
Cohen, P; Corman, JM; Dalkin, BL; Dean, JP; Ellis, WJ; Haugk, K; Lin, DW; Montgomery, B; Mostaghel, E; Nelson, PS; Plymate, SR; Sprenger, CC; Wan, J	1
Fallon, MA; Lee, H; Nathan, DM; Smith, MR	1

Trials

2 trial(s) available for bicalutamide and Obesity

Article	Year
A randomized phase 2 study of bicalutamide with or without metformin for biochemical recurrence in overweight or obese prostate cancer patients (BIMET-1). Prostate cancer and prostatic diseases, 2022, Volume: 25, Issue:4 Topics: Androgen Antagonists; Anilides; Humans; Male; Metformin; Nitriles; Obesity; Overweight; Programmed Cell Death 1 Receptor; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Tosyl Compounds	2022
Response of the insulin-like growth factor (IGF) system to IGF-IR inhibition and androgen deprivation in a neoadjuvant prostate cancer trial: effects of obesity and androgen deprivation. The Journal of clinical endocrinology and metabolism, 2013, Volume: 98, Issue:5 Topics: Adenocarcinoma; Androgen Antagonists; Anilides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Cohort Studies; Goserelin; Humans; Insulin; Insulin Resistance; Insulin-Like Growth Factor Binding Protein 1; Male; Neoadjuvant Therapy; Nitriles; Obesity; Prostatectomy; Prostatic Neoplasms; Receptor, IGF Type 1; Risk; Secondary Prevention; Somatomedins; Tosyl Compounds; United States	2013

Article

Year

A randomized phase 2 study of bicalutamide with or without metformin for biochemical recurrence in overweight or obese prostate cancer patients (BIMET-1).

Prostate cancer and prostatic diseases, 2022, Volume: 25, Issue:4

Topics: Androgen Antagonists; Anilides; Humans; Male; Metformin; Nitriles; Obesity; Overweight; Programmed Cell Death 1 Receptor; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Tosyl Compounds

2022

Response of the insulin-like growth factor (IGF) system to IGF-IR inhibition and androgen deprivation in a neoadjuvant prostate cancer trial: effects of obesity and androgen deprivation.

The Journal of clinical endocrinology and metabolism, 2013, Volume: 98, Issue:5

Topics: Adenocarcinoma; Androgen Antagonists; Anilides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Cohort Studies; Goserelin; Humans; Insulin; Insulin Resistance; Insulin-Like Growth Factor Binding Protein 1; Male; Neoadjuvant Therapy; Nitriles; Obesity; Prostatectomy; Prostatic Neoplasms; Receptor, IGF Type 1; Risk; Secondary Prevention; Somatomedins; Tosyl Compounds; United States

2013

Other Studies

1 other study(ies) available for bicalutamide and Obesity

Article	Year
Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer. Urology, 2008, Volume: 71, Issue:2 Topics: Adipokines; Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Body Composition; Drug Therapy, Combination; Humans; Insulin Resistance; Leuprolide; Male; Nitriles; Obesity; Prospective Studies; Prostatic Neoplasms; Tosyl Compounds	2008